Aetna Just Sent Your Self-Funded Plan a Notice. If You Don't Act, You're Handing Over Control of Your Plan's Legal Rights

If You Don't Act, You're Handing Over Control of Your Plan's Legal Rights

DEADLINE: July 30, 2026. Self-funded plan sponsors using Aetna should review this now. Aetna has issued a 60-day notice asking plan sponsors to authorize Aetna to control litigation decisions for their plan, including the right to opt your plan out of class action settlements and hire legal counsel on your behalf. If you do not opt out by July 30, 2026, Aetna will treat your silence as consent. This post explains what is at stake, why fiduciaries must respond, and how to protect your plan's legal rights.

In early June 2026, self-funded health plan sponsors who use Aetna as their third-party administrator began receiving a notice titled 60-day Notice: Legal Recovery Process. The notice is politely worded, buried in administrative language, and easy to mistake for a routine MSA update.

It is not routine. This is one of the most significant transfers of fiduciary authority we have seen a TPA attempt to extract from its self-funded clients. Every plan sponsor who receives it should review it carefully and opt out by the July 30, 2026 deadline.

What the Aetna Notice Actually Says

Read that carefully. Aetna is asking your plan to:

• Authorize Aetna to decide whether to join or opt out of class action litigation. Including class actions in which Aetna itself, its affiliates, or business partners may be defendants or have financial interests.

• Grant Aetna the right to select legal counsel. With no requirement that counsel be independent of Aetna.

• Give Aetna authority to approve or reject settlements. On your plan's behalf, with no documented requirement to consult you.

• Make this authorization retroactive to your MSA's effective date. Potentially covering legal rights your plan already holds in active litigation.

And if you do nothing, you consent by default.

Why Aetna Is Doing This Now

The notice itself provides a clue. Aetna cites a specific court ruling as the trigger. A federal court in the Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724, E.D. Pa.) ruled that Aetna did not have the contractual authority to opt its self-funded customers out of class action settlements on their behalf.

That case, which has produced over $533 million in end-payor class settlements so far, includes third-party payers as class members entitled to recover damages. Self-funded health plans fall within that group. When Aetna tried to opt those plans out of settlements without explicit authorization, the court said no.

This MSA amendment is Aetna's solution to that problem. By getting plan sponsors to sign away their litigation decision-making authority now, Aetna gains a retroactive legal basis to control class-action participation in all current and future matters.

A federal court ruled that Aetna lacked authority to opt self-funded customers out of class-action settlements without explicit authorization. This notice is Aetna's fix for that problem.

Why This Is a Serious Fiduciary Red Flag

Under ERISA Section 404, a plan fiduciary must act solely in the interest of plan participants and beneficiaries, with the care of a prudent person. Delegating litigation decision-making authority to the TPA, including decisions about whether to participate in class actions that could return money to the plan, constitutes a structural conflict. When that TPA also has a financial interest in the outcome, the conflict is one that fiduciaries should not accept without careful legal review.

Here is the core problem in plain terms:

• Aetna is a potential defendant or interested party in many class actions. Including the Generic Pharmaceuticals Pricing case, drug pricing cases, network disputes, and others. Giving Aetna control over whether your plan opts in or out of those cases creates a direct conflict with your plan's interests.

• Pro-rata allocation is not the same as maximum recovery. Aetna proposes allocating recovered amounts pro rata among all affected customers after deducting its costs. A self-funded plan that opted out and pursued independent counsel could potentially recover a significantly larger, plan-specific share.

• Aetna will retain 10% of future recoveries starting in 2028. This fee is not trivial. For a plan with significant drug spend, class action recoveries can be substantial. Assigning 10% to the TPA to administer a process you did not control and cannot review is a cost with no obvious fiduciary justification.

• Retroactive authorization is legally aggressive. Authorizing Aetna to act retroactively to your MSA effective date could affect legal rights your plan currently holds in litigation that is already underway.

• Silence equals consent. The opt-out structure inverts standard fiduciary practice. You should be asked to grant authority over significant legal decisions affirmatively. Being told that silence constitutes approval is inconsistent with how named fiduciaries should be treated.

Fiduciary duty is not something a TPA can inherit through inaction. If Aetna is deciding your plan's litigation strategy, who is protecting your participants' interests?

What Every Self-Funded Plan Fiduciary Should Do Right Now

The advice is simple and immediate.

• Opt out. Use the opt-out link provided in Aetna's notice. Your deadline is July 30, 2026. Do not wait for your renewal or assume your broker will handle it.

• Document your decision. Save a copy of the opt-out confirmation. Your ERISA fiduciary file should reflect that you received this notice, reviewed it, and made a deliberate, documented decision to preserve your plan's independent litigation authority.

• Review your current MSA with ERISA counsel. Ask counsel whether the retroactive language in the notice has any implications for legal rights your plan currently holds. Given the scope of active generic drug pricing and other class actions, this is not hypothetical.

• Verify that your broker or consultant saw this notice. Some plan sponsors may not have received it directly. If your plan's administrative contact is not the person responsible for ERISA fiduciary compliance, there is a risk that the notice was filed without review.

• Revisit your independent oversight posture. If Aetna is administering your claims, conducting your payment integrity reviews, and now seeking authority over your litigation strategy, you have a single vendor with no external check. Independent claims analysis is the structural counterbalance.

If you cannot locate the notice email, check with your benefits administrator, broker, and anyone else who receives Aetna communications on your plan's behalf. If no one in your organization has it, contact your Aetna account representative to request a copy and written confirmation of your current authorization status. Then, engage ERISA counsel and confirm that your opt-out has been submitted before the July 30 deadline.

The ClaimInformatics Perspective

We are not providing legal advice, and we are not your ERISA counsel. But we are in this space every day, and what we can tell you clearly is this.

The structure of what Aetna is proposing consolidates litigation authority with the same entity that administers your claims, manages your data, controls your cost reporting, and now proposes to represent your interests in court. That is the opposite of the independent oversight model ERISA contemplates.

The ERISA fiduciary standard was designed specifically to protect plan participants from arrangements where the plan sponsor delegates authority to a party with conflicting interests. Handing your TPA the keys to your class action participation is exactly the kind of arrangement that creates fiduciary exposure for you, not for Aetna.

Independent oversight means maintaining the ability to check your vendor's work, challenge their conclusions, and make your own decisions about your plan's legal and financial interests. You cannot do that if you have signed those rights away.

Frequently Asked Questions

What happens if I miss the July 30 opt-out deadline?

According to the notice, Aetna will treat your non-response as consent to the updated MSA language. This means Aetna will have prospective authority to control your plan's litigation decisions, including participation in class actions and settlement approval. If you miss the deadline, contact your Aetna account representative immediately to determine whether a late opt-out is possible and consult with ERISA counsel about your current exposure.

Does opting out affect my plan's other Aetna services?

The notice states that you can opt out of the legal recovery authorization at any time. Opting out should not affect the administrative services Aetna provides under your existing MSA. You are not terminating the relationship; you are preserving your plan's independent authority over litigation decisions.

What is the Generic Pharmaceuticals Pricing class action, and could my plan benefit from it?

MDL No. 2724 in the Eastern District of Pennsylvania is one of the largest antitrust cases in U.S. history, alleging that more than 150 generic drug manufacturers conspired to fix prices, with over $533 million in end-payor class settlements reached to date. Third-party payers, including employers with self-funded prescription drug plans, are included in the end-payor class. If your plan paid for any of the named generic drugs during the class period, your plan may be entitled to a recovery. Allowing Aetna to control whether your plan participates in future settlements in this litigation is a significant financial decision.

Is it a breach of fiduciary duty to accept Aetna's proposal?

We are not your ERISA counsel and cannot make that determination for your specific plan. We can say that ERISA Section 404 requires plan fiduciaries to act solely in the interests of participants and beneficiaries. Delegating litigation authority to a vendor that has its own financial interests in the outcomes of that litigation, without independent legal review, is the type of arrangement that creates fiduciary exposure. Consult ERISA counsel before accepting.

What is the 10% administrative fee Aetna proposes to retain?

Beginning at your next renewal on or after January 1, 2028, Aetna proposes to retain 10% of any recovered amounts as an administrative fee for managing the legal recovery process. This fee is deducted before any pro rata distribution to affected customers. The notice states that this is to align with industry standards, though it does not identify which standard or provide any benchmarking. Your plan should evaluate whether this fee structure, combined with pro rata distribution and the absence of independent oversight of the recovery process, constitutes reasonable compensation under ERISA Section 408(b)(2).

Have questions about what independent claims oversight looks like for your plan? ClaimInformatics provides conflict-free claims analysis with no carrier or TPA relationships. Contact us.